Holen Sie sich die Stockscreener-App
45.11
1.47%
-0.4878
Schlusskurs vom Vortag:
$45.60
Offen:
$44.78
24-Stunden-Volumen:
22,220
Relative Volume:
0.01
Marktkapitalisierung:
$8.22B
Einnahmen:
$2.69B
Nettoeinkommen (Verlust:
$-214.04M
KGV:
-38.56
EPS:
-1.17
Netto-Cashflow:
$98.43M
1W Leistung:
+9.67%
1M Leistung:
-3.16%
6M Leistung:
-35.10%
1J Leistung:
-27.89%
1-Tages-Spanne:
$44.78
$45.53
1-Wochen-Bereich:
$40.80
$46.07
52-Wochen-Spanne:
$39.97
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
45.24 | 8.22B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
421.07 | 161.38B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
194.87 | 133.67B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
439.04 | 33.35B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
105.31 | 29.22B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.04 | 25.37B | 15.41B | 1.37B | 2.11B | 7.50 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Exact Sciences (EXAS): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential - Insider Monkey
Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential - Insider Monkey
Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight - GlobeNewswire Inc.
EXAS Quantitative Stock AnalysisBenjamin Graham - Nasdaq
Exact Sciences Launches New Test To Monitor Cancer Recurrence: Retail’s Optimistic By Stocktwits - Investing.com India
Exact Sciences Launches New Test To Monitor Cancer Recurrence: Retail’s Optimistic - MSN
Exact Sciences launches the Oncodetect MRD test - TipRanks
Exact Sciences (EXAS) Launches Oncodetect Test for Enhanced Cancer Care | EXAS Stock News - GuruFocus
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test | EXAS Stock News - GuruFocus
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test - Yahoo Finance
Market Sentiment Around Loss-Making Exact Sciences Corporation (NASDAQ:EXAS) - simplywall.st
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers - Yahoo Finance
Exact Sciences (EXAS) Validates Oncotype DX Test for Diverse Bre - GuruFocus
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups - The Joplin Globe
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings) - Benzinga
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target - marketscreener.com
Mizuho sets $60 target on Exact Sciences stock, sees outperform - Investing.com
Mizuho sets $60 target on Exact Sciences stock, sees outperform By Investing.com - Investing.com UK
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
Exact Sciences Schedules First Quarter 2025 Earnings Call - The Joplin Globe
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening - BioSpace
Benchmark maintains Buy on Exact Sciences, price target at $65 By Investing.com - Investing.com South Africa
Benchmark maintains Buy on Exact Sciences, price target at $65 - Investing.com
Exact Sciences Positioned for Growth with Upcoming Product Launches and Margin Expansion - TipRanks
High Growth Tech Stocks To Watch In The US March 2025 - Yahoo Finance
Should You Retain Exact Sciences Stock in Your Portfolio Now? - Yahoo Finance
Why Exact Sciences Corporation (EXAS) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Should You Invest in Exact Sciences Corp. (EXAS)? - MSN
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN - Quantisnow
Former Exact Sciences COO Joins Sera Prognostics Board Amid Strategic Expansion - Stock Titan
"Pick Up Your Poop" F Cancer's New Campaign Encourages At-Home Colorectal Cancer Screening - WV News
RBC Capital Initiates Coverage of Exact Sciences (BMV:EXAS) with Sector Perform Recommendation - Nasdaq
Commit To Buy EXACT Sciences At $30, Earn 14% Using Options - Nasdaq
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - Business Wire
Exact Sciences initiated with a Sector Perform at RBC Capital - TipRanks
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner - Joplin Globe
Exact Sciences Triples Industry Average in Employee Engagement, Wins Prestigious Gallup Award - StockTitan
New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX - Business Wire
Charles Schwab Investment Management Inc. Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Stake Increased by Jones Financial Companies Lllp - Defense World
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Exact Sciences at Raymond James Conference: Strategic Growth and Innovation - Investing.com
La Paloma CC: Set to host PGA Tour Champions' Cologuard Classic - The First Call
Here’s What Led Artisan Mid Cap Fund to Trim Exact Sciences Corporation (EXAS) - Yahoo Finance
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exact Sciences Corp-Aktie (EXAS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Conroy Kevin T | President and CEO |
Mar 07 '25 |
Option Exercise |
22.38 |
66,723 |
1,493,261 |
1,203,269 |
| Herriott James | SVP, General Counsel & Sec |
Feb 28 '25 |
Option Exercise |
0.00 |
4,265 |
0 |
16,339 |
| Conroy Kevin T | President and CEO |
Feb 28 '25 |
Option Exercise |
0.00 |
40,310 |
0 |
1,146,965 |
| Baranick Brian | EVP, GM, Precision Oncology |
Feb 28 '25 |
Option Exercise |
0.00 |
9,673 |
0 |
25,106 |
| ORVILLE JACOB A | EVP, GM, Screening |
Feb 28 '25 |
Option Exercise |
0.00 |
9,673 |
0 |
27,728 |
| Condella Sarah | EVP, Human Resources |
Feb 28 '25 |
Option Exercise |
0.00 |
7,738 |
0 |
84,399 |
| Condella Sarah | EVP, Human Resources |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
80,297 |
| Baranick Brian | EVP, GM, Precision Oncology |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
19,841 |
| Herriott James | SVP, General Counsel & Sec |
Feb 25 '25 |
Option Exercise |
0.00 |
1,647 |
0 |
13,738 |
| ORVILLE JACOB A | EVP, GM, Screening |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
22,136 |
0.28%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):